Keros Therapeutics, Inc. (KROS)
NASDAQ: KROS · Real-Time Price · USD
14.21
-0.21 (-1.46%)
Apr 25, 2025, 4:00 PM EDT - Market closed
Keros Therapeutics Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Keros Therapeutics stock have an average target of 25.29, with a low estimate of 15 and a high estimate of 41. The average target predicts an increase of 77.97% from the current stock price of 14.21.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Keros Therapeutics stock from 12 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 2 | 2 | 2 | 2 | 2 |
| Buy | 5 | 5 | 3 | 3 | 3 | 3 |
| Hold | 0 | 4 | 6 | 6 | 6 | 7 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 11 | 11 | 11 | 11 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Truist Securities | Truist Securities | Strong Buy Maintains $43 → $25 | Strong Buy | Maintains | $43 → $25 | +75.93% | Apr 9, 2025 |
| Wedbush | Wedbush | Hold Reiterates $15 | Hold | Reiterates | $15 | +5.56% | Apr 1, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $40 | Strong Buy | Reiterates | $40 | +181.49% | Apr 1, 2025 |
| Wells Fargo | Wells Fargo | Buy Maintains $28 → $26 | Buy | Maintains | $28 → $26 | +82.97% | Feb 27, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $47 → $40 | Strong Buy | Maintains | $47 → $40 | +181.49% | Feb 27, 2025 |
Financial Forecast
Revenue This Year
5.15M
from 3.55M
Increased by 45.10%
Revenue Next Year
9.45M
from 5.15M
Increased by 83.46%
EPS This Year
-3.63
from -5.00
EPS Next Year
-4.32
from -3.63
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 42.0M | 42.0M | 52.5M | ||
| Avg | 5.2M | 9.5M | 17.2M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1,083.1% | 715.4% | 455.6% | ||
| Avg | 45.1% | 83.5% | 82.2% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 0.91 | -2.59 | -2.46 | ||
| Avg | -3.63 | -4.32 | -4.29 | ||
| Low | -5.59 | -5.90 | -6.50 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.